PMCB Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 16:00):

PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States...

Stats
Today's Volume	14 383.00
Average Volume	25 561.00
Market Cap	17.95M
EPS	$0 ( 2024-03-15 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.430
ATR14	$0.0190 (0.90%)

Insider Trading

Date	Person	Action	Amount	type
2023-11-20	Weinstein Robert	Buy	61 248	Stock Option (Right to Buy)
2023-11-20	Walker Wayne Remell	Buy	61 248	Stock Option (Right to Buy)
2023-11-20	Trujillo Carlos	Buy	85 000	Stock Option (Right to Buy)
2023-11-20	Silverman Joshua	Buy	170 000	Stock Option (Right to Buy)
2023-11-20	Schechter Jonathan	Buy	61 248	Stock Option (Right to Buy)

INSIDER POWER
55.61
Last 54 transactions
Buy: 749 992 \| Sell: 831 346

PharmaCyte Biotech, Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

PharmaCyte Biotech, Inc. Financials

Annual	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.220

FY	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.220

FY	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.260

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-2.45

Financial Reports:

No articles found.

PharmaCyte Biotech, Inc.

PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other solid cancerous tumors; a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes, which include encapsulated genetically modified insulin-producing cells; and therapies for cancer based on the constituents of the cannabis plant. It has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes; and the University of Northern Colorado to develop methods for the identification, separation, and quantification of constituents of cannabis. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.